Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis

Abaloparatide

WALTHAM, Mass., Dec. 21, 2014 (GLOBE NEWSWIRE) — Radius Health, Inc. today announced positive top-line 18-month fracture results from the Company’s Phase 3 clinical trial (ACTIVE) evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.

https://in.finance.yahoo.com/news/radius-announces-positive-phase-3-042531179.html

Abaloparatide
BA058
BIM-44058
UNII-AVK0I6HY2U

BA058; BIM-44058; CAS  247062-33-5

MW 3960.5896, MF C174 H300 N56 O49

NAME………C2.29-methyl(22-L-glutamic acid(F>E),23-L-leucine(F>L),25-L-glutamic acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),31-L-leucine(I>L))human parathyroid hormone-related protein-(1-34)-proteinamide
L-Alaninamide, L-alanyl-L-valyl-L-seryl-L-alpha-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-alpha-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-alpha-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-

L-​Alaninamide, L-​alanyl-​L-​valyl-​L-​seryl-​L-​α-​glutamyl-​L-​histidyl-​L-​glutaminyl-​L-​leucyl-​L-​leucyl-​L-​histidyl-​L-​α-​aspartyl-​L-​lysylglycyl-​L-​lysyl-​L-​seryl-​L-​isoleucyl-​L-​glutaminyl-​L-​α-​aspartyl-​L-​leucyl-​L-​arginyl-​L-​arginyl-​L-​arginyl-​L-​α-​glutamyl-​L-​leucyl-​L-​leucyl-​L-​α-​glutamyl-​L-​lysyl-​L-​leucyl-​L-​leucyl-​2-​methylalanyl-​L-​lysyl-​L-​leucyl-​L-​histidyl-​L-​threonyl-

CLINICAL……….https://clinicaltrials.gov/search/intervention=Abaloparatide%20OR%20BA058%20OR%20BIM-44058

BIM-44058 is a 34 amino acid analog of native human PTHrP currently in phase III clinical trials at Radius Health for the treatment of postmenopausal osteoporosis. Radius is also developing a microneedle transdermal patch using a 3M drug delivery system in phase II clinical trials. The drug candidate was originally developed at Biomeasure (a subsidiary of Ipsen), and was subsequently licensed to Radius and Teijin Pharma.

………………………….

PATENT

http://www.google.com/patents/EP2206725A1?cl=en

1. A peptide of the formula:

   [Glu^{22, 25}, Leu^{23, 28}, ³¹, Lys²⁶, Aib²⁹, Nle³⁰]hPTHrP(1-34)NH₂;

   [Glu^{22, 25}, Leu^{23, 28, 30}, ³¹, Lys²⁶, Aib²⁹]hPTHrP(1-34)NH₂; [Glu^{22, 25,29}, Leu^{23, 28, 30, 31}, Lys²⁶]hpTHrP(1-34)NH₂; [Glu^{22, 25, 29}, Leu^{23, 28, 31}, Lys²⁶, Nle³⁰]hPTHrP(1-34)NH₂; [Ser¹, Ile⁵, Met⁸, Asn¹⁰, Leu^{11, 23, 28, 31}, His¹⁴, Cha¹⁵, Glu^{22, 25}, Lys^{26, 30}, Aib²⁹]hPTHrP (1-34)NH₂; [Cha²², Leu^{23, 28, 31}, Glu^{25, 29}, Lys²⁶, Nle³⁰]hPTHrP(1-34)NH₂; [Cha^{7, 11}, ¹⁵]hPTHrP(1-34)NH₂; [Cha^{7, 8, 15}]hPTHrP(1-34)NH₂; [Glu²², Leu^{23, 28}, Aib^{25, 29}, Lys²⁶]hpTHrP(1-34)NH₂; [Aib²⁹]hPTHrP(1-34)NH₂; [Glu^{22, 25}, Leu^{23, 28, 31}, Lys²⁶, Aib^{29, 30}]hPTHrP(1-34)NH₂; [Glu^{22, 25}, Leu^{23, 28, 31}, Lys²⁶, Aib²⁹]hPTHrP(1-34)NH₂; [Glu^{22, 25}, Leu^{23, 28, 31}, Aib^{26, 29}, Lys³⁰] hPTHrP(1-34)NH₂; or [Leu²⁷, Aib²⁹]hPTH(1-34)NH₂; or a pharmaceutically acceptable salt thereof.

…………………

SEE……http://www.google.com.ar/patents/US8148333?cl=en

………………..

SEE…………http://www.google.im/patents/US20090227498?cl=pt